Here's the Deal
Baird's Investment Banking Group is pleased to announce the following transaction:
Science 37, Inc. (“Science 37”) announced that it has closed its previously announced merger with the special purpose acquisition company LifeSci Acquisition II Corp. Through the business combination, shares of common stock of Science 37 began trading on the Nasdaq (NASDAQ: SNCE).
Science 37's mission is to enable universal access to clinical research—making it easier for patients and providers to participate from nearly anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 Clinical Trial Operating System (OS) supports today’s more agile clinical research designs with its full stack, end-to-end technology platform and specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators and connected devices. Configurable to enable any study type, the Science 37 OS can enable up to 15x faster enrollment, 28% better retention and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation and data harmonization. Science 37 is headquartered in Los Angeles, California.
LifeSci Acquisition II Corp. was a special purpose acquisition corporation formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with potential target companies within the Healthcare sector that are poised for rapid growth and have transformational potential. Andrew McDonald, CEO, previously served as the CEO of LifeSci Acquisition Corp. and has been the CEO of Attune Pharmaceuticals since 2015, as well as a founder of both LifeSci Capital and LifeSci Advisors. Michael Rice, COO, co-founded both LifeSci Capital and LifeSci Advisors. David Dobkin, CFO, previously served as the CFO and director of LifeSci Acquisition Corp. LifeSci Acquisition II Corp. is headquartered in New York, New York.
For additional information about this transaction, please contact: